In the future, whether to use EGFR inhibitors such as erlotinib (Tarceva®) and gefitinib (Iressa®) for targeting AREG and decreasing long-term exposure to PM-induced lung cancer patients is worthy of further study. The gene discussed is EGFR; the disease is lung carcinoma.